General Information of Disease (ID: DIS26F9Q)

Disease Name Pancreatic ductal carcinoma
Synonyms
pancreatic tubular adenocarcinoma; ductal adenocarcinoma of pancreas; pancreatic ductal carcinoma; malignant neoplasm of duct of Wirsung; ductal adenocarcinoma of the pancreas; pancreatic duct adenocarcinoma; pancreas ductal adenocarcinoma; pancreatic ductal adenocarcinoma; pancreatic duct cancer
Disease Class 2C10: Pancreatic cancer
Definition
An infiltrating adenocarcinoma that arises from the epithelial cells of the pancreas. It affects males more often than females and the patients are usually over 50 years of age. Microscopically it is characterized by the presence of glandular (ductal) differentiation and desmoplastic stroma formation. Signs and symptoms include pain, loss of weight, and jaundice. It grows rapidly and is usually detected after it has metastasized to other anatomic sites. The prognosis is usually poor.
Disease Hierarchy
DIS3IHTY: Adenocarcinoma
DISKHX7S: Pancreatic adenocarcinoma
DIS26F9Q: Pancreatic ductal carcinoma
ICD Code
ICD-11
ICD-11: 2C10.0
Expand ICD-11
'2C10.0
Disease Identifiers
MONDO ID
MONDO_0005184
UMLS CUI
C1335302
MedGen ID
277490
SNOMED CT ID
792907004

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 3 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Durvalumab DM4PVDY Approved Monoclonal antibody [1]
Gemcitabine DMSE3I7 Approved Small molecular drug [2]
Paclitaxel DMLB81S Approved Small molecular drug [3]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Aldoxorubicin DMHKCIS Phase 3 NA [4]
AM0010 DMGMNUE Phase 3 NA [1]
NIS793 DM8LBYT Phase 2 NA [5]
SBP-101 DMESA9F Phase 1 NA [1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 138 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
AGR2 TT9K86S Limited Biomarker [6]
ARG2 TTV1AG6 Limited Biomarker [7]
BBC3 TT7JUKC Limited Biomarker [8]
CBX7 TTBN3HC Limited Altered Expression [9]
CCN1 TTPK79J Limited Biomarker [10]
CD24 TTCTYNP Limited Altered Expression [11]
CD276 TT6CQUM Limited Biomarker [12]
CDH3 TTARMD9 Limited Biomarker [13]
CHKA TT10AWB Limited Altered Expression [14]
CHST15 TTFK7E1 Limited Biomarker [15]
CLCA1 TT3AF4R Limited Altered Expression [16]
CLDN4 TTMTS9H Limited Biomarker [17]
CXCR2 TT30C9G Limited Biomarker [18]
DCLK1 TTOHTCY Limited Altered Expression [19]
DKK1 TTE3RAC Limited Altered Expression [20]
EIF5A TTIVCNR Limited Genetic Variation [21]
EIF5A2 TTH53G9 Limited Biomarker [22]
FAM83B TT1Q347 Limited Altered Expression [23]
FGF10 TTNPEFX Limited Biomarker [24]
FOLR2 TTT54CI Limited Biomarker [25]
FOXO1 TTLRVIA Limited Altered Expression [26]
GLI1 TTJOMH6 Limited Altered Expression [27]
GPR55 TTNET8J Limited Biomarker [28]
GRK3 TT5A4DX Limited Altered Expression [29]
HHAT TT1VNCG Limited Biomarker [30]
HRH2 TTQHJ1K Limited Biomarker [31]
IMP3 TTEJA2R Limited Altered Expression [32]
IRAK4 TTILUKB Limited Biomarker [33]
ITGB6 TTKQSXZ Limited Biomarker [34]
KLF4 TTTI53X Limited Biomarker [35]
L1CAM TTC9D3K Limited Altered Expression [36]
LASP1 TTZJA87 Limited Altered Expression [37]
LGMN TTPTWV5 Limited Biomarker [38]
MAZ TT059DA Limited Altered Expression [39]
MUC1 TTBHFYQ Limited Biomarker [40]
MUC16 TTC1PS3 Limited Altered Expression [41]
NRP1 TTIPJCB Limited Altered Expression [42]
NSD1 TTTSJ3H Limited Biomarker [43]
NTSR1 TTTUMEP Limited Altered Expression [44]
P4HA1 TTNH25W Limited Altered Expression [45]
PAK4 TT7Y3BZ Limited Biomarker [46]
PDCD1 TTNBFWK Limited Biomarker [47]
PDZK1 TTDTBLM Limited Altered Expression [48]
PKM TT4LOT8 Limited Altered Expression [49]
PLAC1 TTM18HX Limited Altered Expression [50]
PLD1 TT3T17P Limited Altered Expression [51]
PPARGC1B TTKSQ3W Limited Biomarker [52]
PPM1A TTLA7IX Limited Biomarker [53]
PSCA TT9T4AV Limited Altered Expression [54]
REG4 TTVZEHU Limited Altered Expression [55]
RICTOR TT143WL Limited Biomarker [56]
RNF43 TTD91BL Limited Genetic Variation [57]
SCN8A TT54ERL Limited Genetic Variation [58]
SLC8A1 TTCF82X Limited Genetic Variation [59]
SMAD7 TT0J32Z Limited Altered Expression [60]
SPARC TTBQFM7 Limited Altered Expression [61]
SREBF2 TTRQ4AP Limited Biomarker [62]
SSRP1 TTETDKQ Limited Altered Expression [63]
STK33 TTP34DQ Limited Biomarker [64]
TAGLN2 TTP6BIJ Limited Biomarker [65]
TFF1 TTNOJIZ Limited Altered Expression [66]
TK1 TTP3QRF Limited Biomarker [67]
TNC TTUCPMY Limited Altered Expression [68]
TPBG TT70MLA Limited Biomarker [69]
ULK1 TT4D7MJ Limited Biomarker [70]
WNT7A TT8NARC Limited Altered Expression [71]
BRCA2 TTUARD6 Disputed Genetic Variation [72]
CPB1 TT4UJX5 Disputed Biomarker [73]
ITGA11 TTANXZ7 Disputed Altered Expression [74]
KDM3A TTKXS4A Disputed Altered Expression [19]
MCOLN1 TT9XBVO Disputed Biomarker [75]
PDX1 TT8SGZK Disputed Altered Expression [76]
ADAM8 TTQWYMD moderate Altered Expression [77]
ADCYAP1R1 TT5OREU moderate Biomarker [78]
AZGP1 TTUPYLV moderate Altered Expression [79]
CFB TTA0P7K moderate Biomarker [80]
COASY TT4YO0Z moderate Genetic Variation [81]
COL6A3 TT5WCAH moderate Biomarker [82]
CSK TTX6F0Q moderate Genetic Variation [83]
DEPTOR TTLYP6D moderate Altered Expression [84]
DPEP1 TTYUENF moderate Biomarker [85]
FABP5 TTNT2S6 moderate Altered Expression [86]
HNRNPA2B1 TT8UPW6 moderate Biomarker [87]
IDUA TT0IUKX moderate Biomarker [88]
KLK6 TTLPF4X moderate Biomarker [89]
NEK2 TT3VZ24 moderate Altered Expression [90]
PDPK1 TTYMGWX moderate Biomarker [91]
RPL15 TTQRVC9 moderate Altered Expression [92]
SENP1 TTW9HY5 moderate Altered Expression [93]
STK4 TTCPLVN moderate Biomarker [94]
AQP3 TTLDNMQ Strong Biomarker [95]
ARG1 TT7ZQEV Strong Altered Expression [96]
CCKBR TTVFO0U Strong Biomarker [97]
CDC20 TTBKFDV Strong Biomarker [98]
CDC25B TTR0SWN Strong Biomarker [99]
CDK5 TTL4Q97 Strong Posttranslational Modification [100]
CEACAM6 TTIGH2W Strong Biomarker [101]
DCK TTJOCE4 Strong Genetic Variation [102]
DEK TT1NMGV Strong Altered Expression [103]
DLL4 TTV23LH Strong Altered Expression [104]
DYRK1A TTSBVFO Strong Biomarker [105]
DYRK1B TTYGQ8A Strong Biomarker [106]
FOLH1 TT9G4N0 Strong Biomarker [107]
GOT1 TTU507L Strong Biomarker [108]
IDO2 TTALN9W Strong Altered Expression [109]
ISG15 TTVOH3T Strong Altered Expression [110]
LGR5 TTTSGRH Strong Altered Expression [111]
LIPE TTLUQ8E Strong Biomarker [112]
MIA TT5HNVS Strong Genetic Variation [113]
MSLN TT4RXME Strong Biomarker [114]
MUC17 TTVO0JU Strong Biomarker [115]
NEDD9 TT1UREA Strong Altered Expression [116]
NES TTHZ752 Strong Altered Expression [117]
NTF4 TTIM2WO Strong Altered Expression [118]
PMS1 TTX1ISF Strong Biomarker [119]
PRSS1 TT2WR1T Strong Genetic Variation [120]
RABL3 TTYGK57 Strong Genetic Variation [121]
RACK1 TTJ10AL Strong Biomarker [122]
RRM2 TT1S4LJ Strong Altered Expression [123]
SERPINB5 TT1KW50 Strong Biomarker [124]
SLC29A1 TTLXAKE Strong Biomarker [125]
SLC6A14 TTB6H2S Strong Altered Expression [73]
TFAP2A TTDY4BS Strong Altered Expression [126]
TRPM8 TTXDKTO Strong Biomarker [127]
TTK TTP7EGM Strong Biomarker [128]
UCHL5 TTSX29Z Strong Biomarker [129]
XPO1 TTCJUR4 Strong Altered Expression [130]
YAP1 TT8UN2D Strong Biomarker [131]
ADAM9 TTTYQNS Definitive Biomarker [132]
ASPH TT2KHP7 Definitive Biomarker [133]
BUB1 TT78309 Definitive Altered Expression [134]
C1QBP TTWTD7F Definitive Biomarker [135]
CTSE TTLXC4Q Definitive Biomarker [136]
DKK2 TTST5KX Definitive Biomarker [137]
LAPTM4B TTEJQT0 Definitive Biomarker [138]
MAPK12 TTYT93M Definitive Biomarker [139]
PRLR TTBPXMA Definitive Biomarker [140]
VSIR TT51SK8 Definitive Biomarker [141]
------------------------------------------------------------------------------------
⏷ Show the Full List of 138 DTT(s)
This Disease Is Related to 3 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC24A2 DTKRWE8 Limited Biomarker [142]
SLC28A3 DT4YL5R Limited Altered Expression [143]
SLC41A1 DTB37ZE Limited Biomarker [144]
------------------------------------------------------------------------------------
This Disease Is Related to 4 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
CES2 DETHCPD moderate Altered Expression [145]
CYP4F2 DE3GT9C moderate Biomarker [146]
CYP4F3 DEFCMPI moderate Biomarker [146]
EGLN3 DEMQTKH moderate Altered Expression [147]
------------------------------------------------------------------------------------
This Disease Is Related to 218 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ANLN OTXJY54C Limited Biomarker [148]
ANO6 OTTA5KQJ Limited Biomarker [149]
AQP5 OT77GBY8 Limited Altered Expression [150]
ARHGAP15 OT9CKHDC Limited Biomarker [151]
ARHGEF15 OTGHDJFP Limited Altered Expression [152]
ARID1A OTRWDV3P Limited Biomarker [153]
BTF3 OT5ZZFJL Limited Altered Expression [154]
CADM4 OT0TFMFE Limited Altered Expression [155]
CCDC51 OTOJNHNA Limited Biomarker [156]
CCDC68 OT4KF6TL Limited Biomarker [157]
CCNG1 OT17IA9L Limited Altered Expression [158]
CDH15 OTJ1TO02 Limited Biomarker [13]
CLIC4 OT6KTPKD Limited Biomarker [159]
CNN2 OTH3CSXA Limited Altered Expression [160]
COL11A2 OT3BQUBH Limited Genetic Variation [161]
COL9A1 OTWBR27Y Limited Genetic Variation [58]
COL9A2 OT1ZBDBV Limited Genetic Variation [58]
COL9A3 OTCUJOEK Limited Genetic Variation [58]
COMMD7 OTWWJ97D Limited Biomarker [162]
COPS6 OTG9AAG0 Limited Biomarker [163]
CRKL OTOYSD1R Limited Biomarker [164]
CST7 OTQWZUVQ Limited Biomarker [165]
CSTA OT1K68KE Limited Altered Expression [166]
DCLRE1C OTW3KB1I Limited Biomarker [167]
DCX OTISR7K3 Limited Altered Expression [168]
DESI2 OTHUOKOC Limited Altered Expression [169]
DTNBP1 OT9UQT2S Limited Biomarker [170]
DUOX2 OTU14HCN Limited Altered Expression [171]
EFNB2 OT0DCUOM Limited Biomarker [172]
EI24 OTD4NOYS Limited Altered Expression [173]
EIF4G1 OT2CF1E6 Limited Biomarker [174]
EIF6 OTEXMUED Limited Biomarker [175]
EMB OT67E3Q1 Limited Altered Expression [176]
EYA4 OTINGR3Z Limited Biomarker [177]
FBP1 OTQBANEP Limited Altered Expression [178]
FEZF1 OTRX4NOT Limited Biomarker [179]
FLOT2 OTZ0QR5L Limited Biomarker [180]
FUT8 OTJJCVG1 Limited Altered Expression [181]
GAB2 OTBFN705 Limited Biomarker [164]
GOLM1 OTOZSV6O Limited Altered Expression [182]
GPC5 OT8NR7GC Limited Biomarker [183]
GPRC5A OTPOCWR7 Limited Biomarker [184]
HMGN5 OTUUAHVQ Limited Altered Expression [185]
IFIT3 OTPGHZB9 Limited Biomarker [186]
IGF2BP3 OTB97VIK Limited Biomarker [187]
IKBKG OTNWJWSD Limited Biomarker [188]
IMMP2L OT9WGAFD Limited Biomarker [189]
KLF10 OT4F4UGS Limited Biomarker [190]
LTBP2 OTS88GSD Limited Altered Expression [191]
MAP4K5 OTUFGLXE Limited Biomarker [192]
MMUT OTBBBV70 Limited Biomarker [193]
MTSS1 OT5DTDO2 Limited Biomarker [194]
MUC13 OTWKS9MF Limited Altered Expression [195]
MUC4 OTLT11V1 Limited Altered Expression [196]
MUCL3 OTGAD3I0 Limited Biomarker [197]
MYBL2 OTZ3JX8Q Limited Biomarker [198]
MYOF OTRFC3IJ Limited Altered Expression [199]
NECTIN1 OTTE5ZR6 Limited Altered Expression [200]
NEU2 OTW76T35 Limited Biomarker [201]
NUDT1 OTZSES3W Limited Altered Expression [202]
NUPR1 OT4FU8C0 Limited Biomarker [203]
OCIAD1 OTJBY7PV Limited Biomarker [204]
ORM1 OTZKSBRE Limited Altered Expression [205]
PAFAH1B2 OTRDWN2V Limited Altered Expression [206]
PCBP2 OTXCN9CG Limited Altered Expression [207]
PCDH10 OT2GIT0E Limited Altered Expression [208]
PDHX OTG7O271 Limited Genetic Variation [209]
PEAK1 OTVVM637 Limited Biomarker [21]
PF4V1 OT2CXM6L Limited Biomarker [210]
PHLPP1 OTIFXW8D Limited Biomarker [211]
PIGR OT6GLSUL Limited Altered Expression [212]
PREX2 OTYT1J6J Limited Biomarker [213]
PSMD11 OT8KO67V Limited Altered Expression [214]
QRSL1 OTJDU2UG Limited Biomarker [215]
RAB27A OT9SQRWY Limited Altered Expression [216]
RAB27B OTPF9D0K Limited Altered Expression [216]
REG3G OTLIUY8Z Limited Biomarker [217]
RNLS OTVP2WJM Limited Biomarker [218]
RO60 OTLGM5A8 Limited Altered Expression [219]
SAV1 OTSAEV92 Limited Biomarker [220]
SDS OT5WTJ2M Limited Biomarker [221]
SEMA3C OTEGUY7F Limited Biomarker [222]
SERP1 OT60XXUP Limited Biomarker [223]
SKI OT4KJ8F6 Limited Altered Expression [224]
SOX18 OTPUMHWA Limited Biomarker [225]
SOX9 OTVDJFGN Limited Biomarker [226]
SPARCL1 OT74DWMV Limited Altered Expression [227]
SPPL3 OT2HLJF6 Limited Biomarker [189]
TAS2R10 OT4RWZZD Limited Biomarker [228]
TEAD1 OTK6971C Limited Altered Expression [229]
TFAP2C OTUDIW05 Limited Biomarker [230]
TFPI2 OTZCRWOR Limited Altered Expression [229]
TGFBR3 OTQOOUC4 Limited Biomarker [231]
THBS2 OTXET551 Limited Biomarker [232]
ALPG OTCIM29R Disputed Biomarker [233]
ASH2L OT3HG324 Disputed Biomarker [234]
DAXX OTX6O7PL Disputed Genetic Variation [235]
EIF4A1 OTMTBX6N Disputed Biomarker [236]
EIF4A2 OT08H03R Disputed Biomarker [236]
FOXB2 OTJE3RRR Disputed Biomarker [237]
GALNT5 OTCV61V1 Disputed Altered Expression [73]
GIPC1 OTXLVCPJ Disputed Biomarker [238]
KRT10 OTSVRD3Q Disputed Biomarker [239]
RASAL2 OTGMMX6W Disputed Biomarker [240]
RPL17 OTTYMPS6 Disputed Altered Expression [241]
SPATA2 OTOA45GL Disputed Altered Expression [241]
THAP9 OTY4TSJO Disputed Biomarker [242]
TSPAN1 OTZQPIYK Disputed Altered Expression [73]
ADAM15 OTZ7VLTP moderate Altered Expression [243]
AKAP12 OTCVRDDX moderate Posttranslational Modification [244]
AP2A1 OTEFZB21 moderate Altered Expression [126]
B3GALNT1 OT8GFSQL moderate Altered Expression [245]
CD151 OTF3UZS7 moderate Biomarker [246]
CDCA5 OTZLCQ5U moderate Biomarker [247]
CLIC3 OT5KUZ3A moderate Altered Expression [248]
CLPTM1L OTDJWQXI moderate Biomarker [249]
DHX58 OT19BYB1 moderate Biomarker [250]
DLEC1 OTMKKBUW moderate Biomarker [251]
DPYSL3 OTINJV20 moderate Biomarker [252]
DYNLL1 OTR69LHT moderate Biomarker [251]
ESRP1 OTNCS4SL moderate Biomarker [253]
FCN2 OTTHJBKZ moderate Biomarker [247]
FOXL1 OT89XFPN moderate Altered Expression [254]
FRAT1 OT1PS84E moderate Altered Expression [255]
GCHFR OTEOT8GI moderate Biomarker [247]
GOLPH3 OTDLGYM3 moderate Altered Expression [256]
HOXC8 OTJUYU8J moderate Biomarker [257]
ILF2 OTWWVM9X moderate Altered Expression [258]
JADE1 OTBPJIRI moderate Biomarker [259]
KLK10 OTD573EL moderate Altered Expression [89]
LHX2 OTK61NP8 moderate Biomarker [260]
MAP1S OT5WUD4C moderate Biomarker [261]
MNAT1 OTXLOYCB moderate Biomarker [247]
MPEG1 OT7DAO0F moderate Biomarker [88]
MYO10 OTHB78ZQ moderate Altered Expression [262]
NMU OTW9X7BQ moderate Biomarker [263]
NUMB OTMB586Q moderate Biomarker [264]
PA2G4 OT7IG7HT moderate Biomarker [265]
PNKD OT6G9UXN moderate Altered Expression [266]
PODXL OTPNQXF3 moderate Biomarker [267]
PSMG1 OTZ5I6UM moderate Biomarker [78]
QSOX1 OT4ZPK4P moderate Altered Expression [268]
RAB2A OT6SK83U moderate Biomarker [260]
RALGDS OTG36NI7 moderate Altered Expression [269]
RASSF6 OT25GVWY moderate Altered Expression [270]
RNF2 OTFPLOIN moderate Altered Expression [271]
RPS27 OTFXKY7P moderate Biomarker [88]
SRPX2 OT6A63TX moderate Biomarker [272]
STIL OT9799VN moderate Altered Expression [273]
TBX4 OTW58FG4 moderate Altered Expression [274]
TM4SF1 OTY0ECQN moderate Altered Expression [275]
TRIM29 OT2DNESG moderate Altered Expression [276]
TTLL4 OTHEIBQG moderate Altered Expression [277]
APOC1 OTA58CED Strong Genetic Variation [278]
BAG3 OTVXYUDQ Strong Altered Expression [110]
CCL18 OT7JYSK9 Strong Biomarker [279]
CDX2 OTCG4TSY Strong Altered Expression [280]
CEMIP OTK80FYN Strong Altered Expression [281]
COX5A OTP0961M Strong Altered Expression [282]
CPEB4 OTW1SCZW Strong Biomarker [283]
CPOX OTIAY121 Strong Altered Expression [282]
CRABP2 OTY01V9G Strong Altered Expression [284]
DUSP2 OTH54FMR Strong Altered Expression [285]
FERMT2 OTZNPWWX Strong Altered Expression [286]
FXYD3 OT9PPRHE Strong Altered Expression [181]
GATA6 OTO2BC0F Strong Biomarker [215]
GPC1 OTQKRSSV Strong Biomarker [287]
HCLS1 OTX7WGYN Strong Altered Expression [118]
HHLA2 OTYBTVQS Strong Biomarker [288]
HOXB9 OTMVHQOU Strong Biomarker [289]
IGF2BP2 OT4ZSEEE Strong Altered Expression [290]
IGSF9 OTNTKWS2 Strong Altered Expression [291]
IQGAP1 OTZRWTGA Strong Biomarker [292]
KHSRP OTDHZARB Strong Altered Expression [118]
KLF9 OTBFEJRQ Strong Biomarker [293]
LGALS4 OTKQCG0H Strong Altered Expression [294]
LRG1 OTLD0KWA Strong Altered Expression [295]
LUM OTSRC874 Strong Altered Expression [296]
MTA2 OTCCYIQJ Strong Biomarker [297]
MUC20 OTYYE1GK Strong Biomarker [298]
MUC3A OTI4XUDY Strong Biomarker [115]
NRDC OTWBBCXO Strong Biomarker [299]
NSD3 OT3677ZG Strong Biomarker [300]
NTS OTPGDNQS Strong Altered Expression [301]
PALB2 OT6DNDBG Strong Biomarker [302]
PKHD1 OTAH8SMF Strong Genetic Variation [303]
PLEC OTU4XDEG Strong Altered Expression [304]
PPP4C OT4B0TNV Strong Biomarker [305]
PTF1A OT7SWA57 Strong Altered Expression [306]
RHOC OTOLE1FT Strong Genetic Variation [307]
SEL1L OTC0FB7T Strong Altered Expression [308]
SIGLEC7 OTNDLURR Strong Altered Expression [118]
TFIP11 OT7NVSWU Strong Altered Expression [291]
TGIF1 OTN9VHAG Strong Biomarker [309]
AMFR OTQRX7LC Definitive Biomarker [310]
ARHGEF10 OTHJ1Y4I Definitive Biomarker [311]
ARHGEF28 OT3F32IU Definitive Biomarker [311]
ATP6AP2 OT0IABVV Definitive Biomarker [312]
EHF OTY6TPWD Definitive Biomarker [313]
EPS8 OTZ6ES6V Definitive Biomarker [314]
FASTKD2 OTD635WX Definitive Altered Expression [315]
GGPS1 OTVEHG28 Definitive Biomarker [316]
INSM1 OTG8RV8E Definitive Altered Expression [317]
KAT2A OTN0W2SW Definitive Altered Expression [318]
LAMTOR5 OTER0U8L Definitive Biomarker [319]
LIMS1 OT729S0T Definitive Altered Expression [320]
LRPAP1 OT6DVD2Q Definitive Biomarker [321]
MAP2K4 OTZPZX11 Definitive Genetic Variation [322]
MDH1 OTJEO4E8 Definitive Biomarker [323]
MPP7 OT3G3HTZ Definitive Biomarker [323]
NBR1 OTVRL7J9 Definitive Biomarker [310]
NT5C1A OTS7UF36 Definitive Altered Expression [324]
PLEKHM1 OT1SLPGD Definitive Altered Expression [310]
PLIN2 OTRXJ9UN Definitive Altered Expression [325]
POLE OTFM3MMU Definitive Altered Expression [326]
RACGAP1 OTQE8IEH Definitive Biomarker [327]
TMIGD2 OTWWAHTV Definitive Biomarker [141]
TMPO OTL68EL4 Definitive Altered Expression [328]
------------------------------------------------------------------------------------
⏷ Show the Full List of 218 DOT(s)

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Gemcitabine FDA Label
3 Paclitaxel FDA Label
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 ClinicalTrials.gov (NCT04390763) Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC). U.S. National Institutes of Health.
6 Anterior gradient 2 downregulation in a subset of pancreatic ductal adenocarcinoma is a prognostic factor indicative of epithelial-mesenchymal transition.Lab Invest. 2015 Feb;95(2):193-206. doi: 10.1038/labinvest.2014.138. Epub 2014 Nov 24.
7 Critical role for arginase 2 in obesity-associated pancreatic cancer.Nat Commun. 2017 Aug 14;8(1):242. doi: 10.1038/s41467-017-00331-y.
8 Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-B signaling pathway in human pancreatic ductal adenocarcinoma.Int J Mol Sci. 2012;13(1):1186-1208. doi: 10.3390/ijms13011186. Epub 2012 Jan 20.
9 CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer.Oncotarget. 2017 Jan 31;8(5):8010-8021. doi: 10.18632/oncotarget.14037.
10 CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma.Mol Cancer Ther. 2019 Apr;18(4):788-800. doi: 10.1158/1535-7163.MCT-18-0899. Epub 2019 Feb 20.
11 Analysis of the origin of anaplastic pancreatic cancer and the mechanism of its dedifferentiation.J Hepatobiliary Pancreat Sci. 2017 Mar;24(3):176-184. doi: 10.1002/jhbp.429. Epub 2017 Feb 19.
12 Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.Cancer Cell. 2019 Feb 11;35(2):221-237.e8. doi: 10.1016/j.ccell.2019.01.002.
13 Cadherin-1 and cadherin-3 cooperation determines the aggressiveness of pancreatic ductal adenocarcinoma.Br J Cancer. 2018 Feb 20;118(4):546-557. doi: 10.1038/bjc.2017.411. Epub 2017 Nov 21.
14 Choline Kinase Alpha (CHK) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors.Mol Cancer Ther. 2016 Feb;15(2):323-33. doi: 10.1158/1535-7163.MCT-15-0214. Epub 2016 Jan 14.
15 Prognostic impact of carbohydrate sulfotransferase 15 in patients with pancreatic ductal adenocarcinoma.Oncol Lett. 2017 Jun;13(6):4799-4805. doi: 10.3892/ol.2017.6071. Epub 2017 Apr 21.
16 Calcium-activated chloride channel regulator 1 as a prognostic biomarker in pancreatic ductal adenocarcinoma.BMC Cancer. 2018 Nov 12;18(1):1096. doi: 10.1186/s12885-018-5013-2.
17 Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma Using a Radiolabelled Anti-Claudin-4 Monoclonal Antibody.Mol Imaging Biol. 2018 Apr;20(2):292-299. doi: 10.1007/s11307-017-1112-8.
18 Blocking CXCLs-CXCR2 axis in tumor-stromal interactions contributes to survival in a mouse model of pancreatic ductal adenocarcinoma through reduced cell invasion/migration and a shift of immune-inflammatory microenvironment.Oncogenesis. 2019 Jan 18;8(2):8. doi: 10.1038/s41389-018-0117-8.
19 The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 and Promotes Tumorigenesis in Mice.Gastroenterology. 2019 Dec;157(6):1646-1659.e11. doi: 10.1053/j.gastro.2019.08.018. Epub 2019 Aug 20.
20 Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma.Clin Chim Acta. 2019 Jan;488:226-234. doi: 10.1016/j.cca.2018.11.023. Epub 2018 Nov 16.
21 eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth.Cancer Res. 2017 Apr 15;77(8):1997-2007. doi: 10.1158/0008-5472.CAN-16-2594. Epub 2017 Apr 5.
22 N1-guanyl-1, 7-diaminoheptane enhances the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine via the inhibition of eukaryotic translation initiation factor 5A2.Exp Ther Med. 2017 Sep;14(3):2101-2107. doi: 10.3892/etm.2017.4740. Epub 2017 Jul 9.
23 High Expression of FAM83B Predicts Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma and Correlates with Cell Cycle and Cell Proliferation.J Cancer. 2017 Sep 12;8(16):3154-3165. doi: 10.7150/jca.20086. eCollection 2017.
24 Emerging Roles of Fibroblast Growth Factor 10 in Cancer.Front Genet. 2018 Oct 24;9:499. doi: 10.3389/fgene.2018.00499. eCollection 2018.
25 Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma.Oncotarget. 2017 Jun 6;8(23):37646-37656. doi: 10.18632/oncotarget.16841.
26 MiR-27a-regulated FOXO1 promotes pancreatic ductal adenocarcinoma cell progression by enhancing Wnt/-catenin signaling activity.Am J Transl Res. 2019 May 15;11(5):3069-3080. eCollection 2019.
27 Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation.Cancer Res. 2016 Dec 1;76(23):7049-7058. doi: 10.1158/0008-5472.CAN-16-0715. Epub 2016 Oct 6.
28 GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine.Oncogene. 2018 Dec;37(49):6368-6382. doi: 10.1038/s41388-018-0390-1. Epub 2018 Jul 30.
29 High expression of GRK3 is associated with favorable prognosis in pancreatic ductal adenocarcinoma.Pathol Res Pract. 2018 Feb;214(2):228-232. doi: 10.1016/j.prp.2017.11.013. Epub 2017 Nov 20.
30 Hedgehog acyltransferase as a target in pancreatic ductal adenocarcinoma. Oncogene. 2015 Jan 8;34(2):263-8.
31 Metformin as an Adjunctive Therapy for Pancreatic Cancer: A Review of the Literature on Its Potential Therapeutic Use.Dig Dis Sci. 2018 Nov;63(11):2840-2852. doi: 10.1007/s10620-018-5233-y. Epub 2018 Aug 29.
32 The involvement of insulin-like growth factor 2 binding protein 3 (IMP3) in pancreatic cancer cell migration, invasion, and adhesion.BMC Cancer. 2015 Apr 11;15:266. doi: 10.1186/s12885-015-1251-8.
33 Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma.Clin Cancer Res. 2017 Apr 1;23(7):1748-1759. doi: 10.1158/1078-0432.CCR-16-1121. Epub 2016 Oct 4.
34 Integrin 6 acts as an unfavorable prognostic indicator and promotes cellular malignant behaviors via ERK-ETS1 pathway in pancreatic ductal adenocarcinoma (PDAC).Tumour Biol. 2016 Apr;37(4):5117-31. doi: 10.1007/s13277-015-4353-7. Epub 2015 Nov 7.
35 Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma.Int J Oncol. 2017 Oct;51(4):1239-1248. doi: 10.3892/ijo.2017.4099. Epub 2017 Aug 22.
36 L1CAM induces perineural invasion of pancreas cancer cells by upregulation of metalloproteinase expression.Oncogene. 2019 Jan;38(4):596-608. doi: 10.1038/s41388-018-0458-y. Epub 2018 Aug 31.
37 LASP1 is a HIF1 target gene critical for metastasis of pancreatic cancer.Cancer Res. 2015 Jan 1;75(1):111-9. doi: 10.1158/0008-5472.CAN-14-2040. Epub 2014 Nov 10.
38 Asparaginyl endopeptidase enhances pancreatic ductal adenocarcinoma cell invasion in an exosome-dependent manner and correlates with poor prognosis.Int J Oncol. 2018 May;52(5):1651-1660. doi: 10.3892/ijo.2018.4318. Epub 2018 Mar 15.
39 The MAZ transcription factor is a downstream target of the oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell invasion via CRAF-ERK signaling.J Biol Chem. 2018 Mar 23;293(12):4334-4349. doi: 10.1074/jbc.RA117.000333. Epub 2018 Feb 6.
40 Assessment of tumor characteristics based on glycoform analysis of membrane-tethered MUC1.Lab Invest. 2017 Sep;97(9):1103-1113. doi: 10.1038/labinvest.2017.53. Epub 2017 Jun 5.
41 Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes ofpancreatic ductal adenocarcinoma.Surgery. 2017 Feb;161(2):373-384. doi: 10.1016/j.surg.2016.08.005. Epub 2016 Nov 9.
42 VEGF receptor-2/neuropilin 1 trans-complex formation between endothelial and tumor cells is an independent predictor of pancreatic cancer survival.J Pathol. 2018 Nov;246(3):311-322. doi: 10.1002/path.5141. Epub 2018 Sep 4.
43 Expression and prognostic value of NSD1 and SETD2 in pancreatic ductal adenocarcinoma and its precursor lesions.Pathology. 2019 Jun;51(4):392-398. doi: 10.1016/j.pathol.2019.02.005. Epub 2019 May 3.
44 Preclinical Evaluation of (68)Ga-DOTA-NT-20.3: A Promising PET Imaging Probe To Discriminate Human Pancreatic Ductal Adenocarcinoma from Pancreatitis.Mol Pharm. 2019 Jun 3;16(6):2776-2784. doi: 10.1021/acs.molpharmaceut.9b00283. Epub 2019 May 3.
45 P4HA1/HIF1 feedback loop drives the glycolytic and malignant phenotypes of pancreatic cancer.Biochem Biophys Res Commun. 2019 Aug 27;516(3):606-612. doi: 10.1016/j.bbrc.2019.06.096. Epub 2019 Jun 22.
46 Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.Mol Cancer Ther. 2017 Jan;16(1):76-87. doi: 10.1158/1535-7163.MCT-16-0205. Epub 2016 Nov 15.
47 A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.J Immunother Cancer. 2019 Aug 29;7(1):233. doi: 10.1186/s40425-019-0703-0.
48 PDZ-containing 1 acts as a suppressor of pancreatic cancer by regulating PTEN phosphorylation.Oncotarget. 2017 Aug 24;8(42):72893-72909. doi: 10.18632/oncotarget.20552. eCollection 2017 Sep 22.
49 Upregulation of pyruvate kinase M2 expression by fatty acid synthase contributes to gemcitabine resistance in pancreatic cancer.Oncol Lett. 2018 Feb;15(2):2211-2217. doi: 10.3892/ol.2017.7598. Epub 2017 Dec 13.
50 Expression and clinical significance of placenta-specific 1 in pancreatic ductal adenocarcinoma.Tumour Biol. 2017 Jun;39(6):1010428317699131. doi: 10.1177/1010428317699131.
51 Simultaneous high expression of PLD1 and Sp1 predicts a poor prognosis for pancreatic ductal adenocarcinoma patients.Oncotarget. 2016 Nov 29;7(48):78557-78565. doi: 10.18632/oncotarget.12447.
52 The FOXO3/PGC-1 signaling axis is essential for cancer stem cell properties of pancreatic ductal adenocarcinoma.J Biol Chem. 2017 Jun 30;292(26):10813-10823. doi: 10.1074/jbc.M116.772111. Epub 2017 May 15.
53 Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.Hum Pathol. 2016 Sep;55:151-8. doi: 10.1016/j.humpath.2016.05.002. Epub 2016 May 16.
54 Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody.J Nucl Med. 2018 Sep;59(9):1398-1405. doi: 10.2967/jnumed.117.207332. Epub 2018 Mar 30.
55 Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma.Tumour Biol. 2018 Mar;40(3):1010428318761494. doi: 10.1177/1010428318761494.
56 Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models.Oncotarget. 2017 Apr 11;8(15):24491-24505. doi: 10.18632/oncotarget.15524.
57 Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors.Nat Med. 2017 Jan;23(1):60-68. doi: 10.1038/nm.4219. Epub 2016 Nov 21.
58 Multiplex Enrichment and Detection of Rare KRAS Mutations in Liquid Biopsy Samples using Digital Droplet Pre-Amplification.Anal Chem. 2019 Jun 18;91(12):7516-7523. doi: 10.1021/acs.analchem.8b01605. Epub 2019 May 24.
59 Functional role of BTB and CNC Homology 1 gene in pancreatic cancer and its association with survival in patients treated with gemcitabine.Theranostics. 2018 May 23;8(12):3366-3379. doi: 10.7150/thno.23978. eCollection 2018.
60 miR-367 promotes epithelial-to-mesenchymal transition and invasion of pancreatic ductal adenocarcinoma cells by targeting the Smad7-TGF- signalling pathway.Br J Cancer. 2015 Apr 14;112(8):1367-75. doi: 10.1038/bjc.2015.102. Epub 2015 Mar 17.
61 The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection.J Cancer. 2019 Jan 1;10(3):627-633. doi: 10.7150/jca.28660. eCollection 2019.
62 Cilia loss sensitizes cells to transformation by activating the mevalonate pathway.J Exp Med. 2018 Jan 2;215(1):177-195. doi: 10.1084/jem.20170399. Epub 2017 Dec 13.
63 SOX9 inhibits -TrCP-mediated protein degradation to promote nuclear GLI1 expression and cancer stem cell properties.J Cell Sci. 2015 Mar 15;128(6):1123-38. doi: 10.1242/jcs.162164. Epub 2015 Jan 27.
64 STK33 Promotes Growth and Progression of Pancreatic Cancer as a Critical Downstream Mediator of HIF1.Cancer Res. 2017 Dec 15;77(24):6851-6862. doi: 10.1158/0008-5472.CAN-17-0067. Epub 2017 Oct 16.
65 Role of transgelin-2 in diabetes-associated pancreatic ductal adenocarcinoma.Oncotarget. 2017 Jul 25;8(30):49592-49604. doi: 10.18632/oncotarget.17519.
66 Trefoil factor family 1 expression in the invasion front is a poor prognostic factor associated with lymph node metastasis in pancreatic cancer.Pancreatology. 2017 Sep-Oct;17(5):782-787. doi: 10.1016/j.pan.2017.07.188. Epub 2017 Jul 26.
67 Thymidine kinase 1 silencing retards proliferative activity of pancreatic cancer cell via E2F1-TK1-P21 axis.Cell Prolif. 2018 Jun;51(3):e12428. doi: 10.1111/cpr.12428. Epub 2017 Dec 20.
68 Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma.Pancreas. 2019 Jan;48(1):43-48. doi: 10.1097/MPA.0000000000001195.
69 Trophoblast glycoprotein promotes pancreatic ductal adenocarcinoma cell metastasis through Wnt/planar cell polarity signaling.Mol Med Rep. 2015 Jul;12(1):503-9. doi: 10.3892/mmr.2015.3412. Epub 2015 Mar 4.
70 LncRNA PVT1 triggers Cyto-protective autophagy and promotes pancreatic ductal adenocarcinoma development via the miR-20a-5p/ULK1 Axis.Mol Cancer. 2018 Jul 12;17(1):98. doi: 10.1186/s12943-018-0845-6.
71 High expression of WNT7A predicts poor prognosis and promote tumor metastasis in pancreatic ductal adenocarcinoma.Sci Rep. 2018 Oct 25;8(1):15792. doi: 10.1038/s41598-018-34094-3.
72 Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma.Int J Cancer. 2019 Aug 1;145(3):686-693. doi: 10.1002/ijc.32127. Epub 2019 Feb 7.
73 Screening and validating the core biomarkers in patients with pancreatic ductal adenocarcinoma.Math Biosci Eng. 2019 Nov 6;17(1):910-927. doi: 10.3934/mbe.2020048.
74 111 Integrin is Induced in a Subset of Cancer-Associated Fibroblasts in Desmoplastic Tumor Stroma and Mediates In Vitro Cell Migration.Cancers (Basel). 2019 Jun 1;11(6):765. doi: 10.3390/cancers11060765.
75 MCOLN1 Promotes Proliferation and Predicts Poor Survival of Patients with Pancreatic Ductal Adenocarcinoma.Dis Markers. 2019 Aug 5;2019:9436047. doi: 10.1155/2019/9436047. eCollection 2019.
76 PDX1, a key factor in pancreatic embryogenesis, can exhibit antimetastatic activity in pancreatic ductal adenocarcinoma.Cancer Manag Res. 2019 Jul 26;11:7077-7087. doi: 10.2147/CMAR.S209940. eCollection 2019.
77 ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer.J Cell Mol Med. 2007 Sep-Oct;11(5):1162-74. doi: 10.1111/j.1582-4934.2007.00082.x.
78 Activation of p16 gene silenced by DNA methylation in cancer cells by phosphoramidate derivatives of 2'-deoxyzebularine.J Med Chem. 2008 Dec 11;51(23):7593-601. doi: 10.1021/jm8005965.
79 AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial transdifferentiation by inhibiting TGF--mediated ERK signaling.Oncogene. 2010 Sep 16;29(37):5146-58. doi: 10.1038/onc.2010.258. Epub 2010 Jun 28.
80 Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma.J Proteome Res. 2014 Nov 7;13(11):4878-88. doi: 10.1021/pr5002719. Epub 2014 Aug 8.
81 Emerging frontiers in pancreatic cancer research: elaboration of key genes, cells and the extracellular milieu.Curr Opin Gastroenterol. 2012 Sep;28(5):516-22. doi: 10.1097/MOG.0b013e3283567f69.
82 Clinical significance of serum COL6A3 in pancreatic ductal adenocarcinoma.J Gastrointest Surg. 2014 Jan;18(1):7-15. doi: 10.1007/s11605-013-2326-y. Epub 2013 Sep 4.
83 Oncogenic Ras/Src cooperativity in pancreatic neoplasia.Oncogene. 2011 May 5;30(18):2123-34. doi: 10.1038/onc.2010.589. Epub 2011 Jan 17.
84 DEPTOR has growth suppression activity against pancreatic cancer cells.Oncotarget. 2014 Dec 30;5(24):12811-9. doi: 10.18632/oncotarget.2659.
85 DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.PLoS One. 2012;7(2):e31507. doi: 10.1371/journal.pone.0031507. Epub 2012 Feb 20.
86 Molecular determinants of retinoic acid sensitivity in pancreatic cancer.Clin Cancer Res. 2012 Jan 1;18(1):280-9. doi: 10.1158/1078-0432.CCR-11-2165. Epub 2011 Oct 18.
87 Emergence of heterogeneous nuclear ribonucleoprotein A2/B1 vs loss of E-cadherin: their reciprocal immunoexpression profiles in human pancreatic cancer.Ann Diagn Pathol. 2013 Feb;17(1):14-7. doi: 10.1016/j.anndiagpath.2012.04.004. Epub 2012 May 22.
88 Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715.Mol Cancer Ther. 2014 Feb;13(2):307-315. doi: 10.1158/1535-7163.MCT-13-0324. Epub 2013 Nov 26.
89 Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma.Br J Cancer. 2008 Nov 4;99(9):1484-92. doi: 10.1038/sj.bjc.6604717. Epub 2008 Oct 14.
90 Abnormal expression of Nek2 in pancreatic ductal adenocarcinoma: a novel marker for prognosis.Int J Clin Exp Pathol. 2014 Apr 15;7(5):2462-9. eCollection 2014.
91 Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer.Cancer Cell. 2013 Mar 18;23(3):406-20. doi: 10.1016/j.ccr.2013.01.023. Epub 2013 Feb 28.
92 Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma.Oncotarget. 2015 Nov 10;6(35):37028-42. doi: 10.18632/oncotarget.5939.
93 SUMO-specific protease 1 regulates pancreatic cancer cell proliferation and invasion by targeting MMP-9.Tumour Biol. 2014 Dec;35(12):12729-35. doi: 10.1007/s13277-014-2598-1. Epub 2014 Sep 13.
94 Spatiotemporal proteomic analyses during pancreas cancer progression identifies serine/threonine stress kinase 4 (STK4) as a novel candidate biomarker for early stage disease.Mol Cell Proteomics. 2014 Dec;13(12):3484-96. doi: 10.1074/mcp.M113.036517. Epub 2014 Sep 15.
95 AQP1 and AQP3 Expression are Associated With Severe Symptoms and Poor-prognosis of the Pancreatic Ductal Adenocarcinoma.Appl Immunohistochem Mol Morphol. 2019 Jan;27(1):40-47. doi: 10.1097/PAI.0000000000000523.
96 CD13(hi) Neutrophil-like myeloid-derived suppressor cells exert immune suppression through Arginase 1 expression in pancreatic ductal adenocarcinoma.Oncoimmunology. 2017 Jan 9;6(2):e1258504. doi: 10.1080/2162402X.2016.1258504. eCollection 2017.
97 Targeting cholecystokinin-2 receptor for pancreatic cancer chemoprevention.Mol Carcinog. 2019 Oct;58(10):1908-1918. doi: 10.1002/mc.23084. Epub 2019 Jul 16.
98 Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.J Hematol Oncol. 2012 Apr 4;5:15. doi: 10.1186/1756-8722-5-15.
99 MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B.Lab Invest. 2011 Oct;91(10):1472-9. doi: 10.1038/labinvest.2011.99. Epub 2011 Jun 27.
100 CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax.Mol Pharmacol. 2019 Oct;96(4):419-429. doi: 10.1124/mol.119.116855.
101 Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) in Pancreatic Ductal Adenocarcinoma (PDA): An integrative analysis of a novel therapeutic target.Sci Rep. 2019 Dec 4;9(1):18347. doi: 10.1038/s41598-019-54545-9.
102 dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study.Medicine (Baltimore). 2016 Mar;95(10):e2936. doi: 10.1097/MD.0000000000002936.
103 Expression of DEK in pancreatic cancer and its correlation with clinicopathological features and prognosis.J Cancer. 2019 Jan 29;10(4):911-917. doi: 10.7150/jca.27405. eCollection 2019.
104 Overexpressions of DLL4 and CD105 are Associated with Poor Prognosis of Patients with Pancreatic Ductal Adenocarcinoma.Pathol Oncol Res. 2015 Sep;21(4):1141-7. doi: 10.1007/s12253-015-9937-4. Epub 2015 May 19.
105 Licocoumarone induces BxPC-3 pancreatic adenocarcinoma cell death by inhibiting DYRK1A. Chem Biol Interact. 2020 Jan 25;316:108913. doi: 10.1016/j.cbi.2019.108913. Epub 2019 Dec 12.
106 Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells.Cancer Biol Ther. 2009 Sep;8(17):1671-9. doi: 10.4161/cbt.8.17.9322. Epub 2009 Sep 20.
107 Neovascular Prostate-Specific Membrane Antigen Expression Is Associated with Improved Overall Survival under Palliative Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma.Biomed Res Int. 2017;2017:2847303. doi: 10.1155/2017/2847303. Epub 2017 Oct 25.
108 Aspulvinone O, a natural inhibitor of GOT1 suppresses pancreatic ductal adenocarcinoma cells growth by interfering glutamine metabolism.Cell Commun Signal. 2019 Aug 30;17(1):111. doi: 10.1186/s12964-019-0425-4.
109 Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers.Clin Cancer Res. 2019 Jan 15;25(2):724-734. doi: 10.1158/1078-0432.CCR-18-0814. Epub 2018 Sep 28.
110 BAG3 deletion suppresses stem cell-like features of pancreatic ductal adenocarcinoma via translational suppression of ISG15.Biochim Biophys Acta Mol Cell Res. 2019 May;1866(5):819-827. doi: 10.1016/j.bbamcr.2019.02.008. Epub 2019 Feb 14.
111 Correlation of clinicopathological features and leucine-rich repeat-containing G-protein-coupled receptor 5 expression in pancreatic ductal adenocarcinoma.Pathol Res Pract. 2019 Nov;215(11):152623. doi: 10.1016/j.prp.2019.152623. Epub 2019 Sep 5.
112 Deficiency in hormone-sensitive lipase accelerates the development of pancreatic cancer in conditional KrasG12D mice.BMC Cancer. 2018 Aug 7;18(1):797. doi: 10.1186/s12885-018-4713-y.
113 Differentially Expressed microRNAs in MIA PaCa-2 and PANC-1 Pancreas Ductal Adenocarcinoma Cell Lines are Involved in Cancer Stem Cell Regulation.Int J Mol Sci. 2019 Sep 10;20(18):4473. doi: 10.3390/ijms20184473.
114 Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.Mol Ther. 2019 Nov 6;27(11):1919-1929. doi: 10.1016/j.ymthe.2019.07.015. Epub 2019 Jul 30.
115 Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Le(x) antigen in pancreatic intraepithelial neoplasia.Pancreas. 2003 Apr;26(3):e48-54. doi: 10.1097/00006676-200304000-00022.
116 Immunohistochemical expression of NEDD9, E-cadherin and -catenin and their prognostic significance in pancreatic ductal adenocarcinoma (PDAC).Bosn J Basic Med Sci. 2018 Aug 1;18(3):246-251. doi: 10.17305/bjbms.2018.2378.
117 Stem cell marker nestin is critical for TGF-1-mediated tumor progression in pancreatic cancer.Mol Cancer Res. 2013 Jul;11(7):768-79. doi: 10.1158/1541-7786.MCR-12-0511. Epub 2013 Apr 3.
118 Reverse transcription-PCR analysis of laser-captured cells points to potential paracrine and autocrine actions of neurotrophins in pancreatic cancer.Clin Cancer Res. 2003 Nov 1;9(14):5127-36.
119 Immune responses to DNA mismatch repair enzymes hMSH2 and hPMS1 in patients with pancreatic cancer, dermatomyositis and polymyositis.Int J Cancer. 2005 Oct 10;116(6):925-33. doi: 10.1002/ijc.21118.
120 Cationic trypsinogen mutations and pancreatitis.Clin Lab Med. 2005 Mar;25(1):39-59. doi: 10.1016/j.cll.2004.12.004.
121 Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer. Nat Genet. 2019 Sep;51(9):1308-1314. doi: 10.1038/s41588-019-0475-y. Epub 2019 Aug 12.
122 Downregulated expression of RACK1 results in pancreatic cancer growth and metastasis.Onco Targets Ther. 2019 Feb 1;12:1007-1020. doi: 10.2147/OTT.S176101. eCollection 2019.
123 Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.PLoS One. 2013;8(1):e53436. doi: 10.1371/journal.pone.0053436. Epub 2013 Jan 15.
124 SERPINB5 Promoter Hypomethylation Differentiates Pancreatic Ductal Adenocarcinoma From Pancreatitis.Pancreas. 2016 May-Jun;45(5):743-7. doi: 10.1097/MPA.0000000000000526.
125 Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy?.Cancers (Basel). 2019 Oct 23;11(11):1621. doi: 10.3390/cancers11111621.
126 Aberrant expressions of AP-2 splice variants in pancreatic cancer.Pancreas. 2011 Jul;40(5):695-700. doi: 10.1097/MPA.0b013e31821f2715.
127 N-glycosylation of the transient receptor potential melastatin 8 channel is altered in pancreatic cancer cells.Tumour Biol. 2017 Aug;39(8):1010428317720940. doi: 10.1177/1010428317720940.
128 Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability.PLoS One. 2017 Apr 5;12(4):e0174863. doi: 10.1371/journal.pone.0174863. eCollection 2017.
129 Positive cytoplasmic UCHL5 tumor expression in gastric cancer is linked to improved prognosis.PLoS One. 2018 Feb 23;13(2):e0193125. doi: 10.1371/journal.pone.0193125. eCollection 2018.
130 DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma.Cancers (Basel). 2019 Aug 2;11(8):1101. doi: 10.3390/cancers11081101.
131 YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma.JCI Insight. 2019 Nov 1;4(21):e130811. doi: 10.1172/jci.insight.130811.
132 ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma.Mol Oncol. 2019 Feb;13(2):456-479. doi: 10.1002/1878-0261.12426. Epub 2019 Jan 9.
133 Anti-tumor activity of antibody drug conjugate targeting aspartate--hydroxylase in pancreatic ductal adenocarcinoma.Cancer Lett. 2019 May 1;449:87-98. doi: 10.1016/j.canlet.2019.02.006. Epub 2019 Feb 12.
134 High expression of CDK1 and BUB1 predicts poor prognosis of pancreatic ductal adenocarcinoma.Gene. 2019 Jun 15;701:15-22. doi: 10.1016/j.gene.2019.02.081. Epub 2019 Mar 18.
135 High cytoplasm HABP1 expression as a predictor of poor survival and late tumor stage in pancreatic ductal adenocarcinoma patients.Eur J Surg Oncol. 2019 Feb;45(2):207-212. doi: 10.1016/j.ejso.2018.09.020. Epub 2018 Oct 21.
136 Cathepsin E expression and activity: Role in the detection and treatment of pancreatic cancer.Pancreatology. 2019 Oct;19(7):951-956. doi: 10.1016/j.pan.2019.09.009. Epub 2019 Sep 20.
137 DKK2 Impairs Tumor Immunity Infiltration and Correlates with Poor Prognosis in Pancreatic Ductal Adenocarcinoma.J Immunol Res. 2019 Sep 8;2019:8656282. doi: 10.1155/2019/8656282. eCollection 2019.
138 Clinical impact of circulating LAPTM4B-35 in pancreatic ductal adenocarcinoma.J Cancer Res Clin Oncol. 2019 May;145(5):1165-1178. doi: 10.1007/s00432-019-02863-w. Epub 2019 Feb 18.
139 MicroRNA-132 Plays an Independent Prognostic Role in Pancreatic Ductal Adenocarcinoma and Acts as a Tumor Suppressor.Technol Cancer Res Treat. 2019 Jan 1;18:1533033818824314. doi: 10.1177/1533033818824314.
140 Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.Gastroenterology. 2020 Apr;158(5):1433-1449.e27. doi: 10.1053/j.gastro.2019.11.279. Epub 2019 Nov 29.
141 B7-H5/CD28H is a co-stimulatory pathway and correlates with improved prognosis in pancreatic ductal adenocarcinoma.Cancer Sci. 2019 Feb;110(2):530-539. doi: 10.1111/cas.13914. Epub 2019 Jan 16.
142 A SLC24A2 Gene Variant Uncovered in Pancreatic Ductal Adenocarcinoma by Whole Exome Sequencing.Tohoku J Exp Med. 2017 Apr;241(4):287-295. doi: 10.1620/tjem.241.287.
143 TGF--induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.Carcinogenesis. 2016 Nov 1;37(11):1041-1051. doi: 10.1093/carcin/bgw093.
144 Magnesium transporter protein solute carrier family 41 member 1 suppresses human pancreatic ductal adenocarcinoma through magnesium-dependent Akt/mTOR inhibition and bax-associated mitochondrial apoptosis.Aging (Albany NY). 2019 May 8;11(9):2681-2698. doi: 10.18632/aging.101940.
145 Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma.J Natl Cancer Inst. 2015 May 29;107(8):djv132. doi: 10.1093/jnci/djv132. Print 2015 Aug.
146 Differential expression of cytochrome P450 omega-hydroxylase isoforms and their association with clinicopathological features in pancreatic ductal adenocarcinoma.Ann Surg Oncol. 2013 Dec;20 Suppl 3:S636-43. doi: 10.1245/s10434-013-3128-x. Epub 2013 Jul 12.
147 Prolyl-4-hydroxylase 3 (PHD3) expression is downregulated during epithelial-to-mesenchymal transition.PLoS One. 2013 Dec 18;8(12):e83021. doi: 10.1371/journal.pone.0083021. eCollection 2013.
148 Regulation of actin-binding protein ANLN by antitumor miR-217 inhibits cancer cell aggressiveness in pancreatic ductal adenocarcinoma.Oncotarget. 2017 May 29;8(32):53180-53193. doi: 10.18632/oncotarget.18261. eCollection 2017 Aug 8.
149 CCR7 regulates ANO6 to promote migration of pancreatic ductal adenocarcinoma cells via the ERK signaling pathway.Oncol Lett. 2018 Aug;16(2):2599-2605. doi: 10.3892/ol.2018.8962. Epub 2018 Jun 13.
150 Differential expression of aquaporin-3 and aquaporin-5 in pancreatic ductal adenocarcinoma.J Surg Oncol. 2017 Jun;115(8):980-996. doi: 10.1002/jso.24605. Epub 2017 May 4.
151 Decreased expression of ARHGAP15 promotes the development of colorectal cancer through PTEN/AKT/FOXO1 axis.Cell Death Dis. 2018 Jun 4;9(6):673. doi: 10.1038/s41419-018-0707-6.
152 ARHGEF15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of the cancer cells.Mol Cancer. 2016 May 4;15(1):32. doi: 10.1186/s12943-016-0516-4.
153 Loss of ARID1A Expression Correlates With Tumor Differentiation and Tumor Progression Stage in Pancreatic Ductal Adenocarcinoma.Technol Cancer Res Treat. 2018 Jan 1;17:1533034618754475. doi: 10.1177/1533034618754475.
154 Basic transcription factor 3 (BTF3) regulates transcription of tumor-associated genes in pancreatic cancer cells.Cancer Biol Ther. 2007 Mar;6(3):367-76. doi: 10.4161/cbt.6.3.3704. Epub 2007 Mar 13.
155 Clinicopathological significance of Necl-4 expression in pancreatic ductal adenocarcinoma.J Clin Pathol. 2017 Jul;70(7):619-624. doi: 10.1136/jclinpath-2016-204028. Epub 2016 Dec 15.
156 Regulation of Proliferation by a Mitochondrial Potassium Channel in Pancreatic Ductal Adenocarcinoma Cells.Front Oncol. 2017 Sep 29;7:239. doi: 10.3389/fonc.2017.00239. eCollection 2017.
157 Coiled-coil domain containing 68 (CCDC68) demonstrates a tumor-suppressive role in pancreatic ductal adenocarcinoma.Oncogene. 2015 Aug 6;34(32):4238-47. doi: 10.1038/onc.2014.357. Epub 2014 Nov 10.
158 The C/EBP-LINC01133 axis promotes cell proliferation in pancreatic ductal adenocarcinoma through upregulation of CCNG1.Cancer Lett. 2018 May 1;421:63-72. doi: 10.1016/j.canlet.2018.02.020. Epub 2018 Feb 16.
159 Association of chloride intracellular channel 4 and Indian hedgehog proteins with survival of patients with pancreatic ductal adenocarcinoma.Int J Exp Pathol. 2016 Dec;97(6):422-429. doi: 10.1111/iep.12213. Epub 2017 Feb 16.
160 Increased expression of calponin 2 is a positive prognostic factor in pancreatic ductal adenocarcinoma.Oncotarget. 2017 May 9;8(34):56428-56442. doi: 10.18632/oncotarget.17701. eCollection 2017 Aug 22.
161 Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review.Cancer Biol Ther. 2019;20(7):949-955. doi: 10.1080/15384047.2019.1595274. Epub 2019 Apr 19.
162 COMMD7 functions as molecular target in pancreatic ductal adenocarcinoma.Mol Carcinog. 2017 Feb;56(2):607-624. doi: 10.1002/mc.22520. Epub 2016 Jul 8.
163 CSN6 expression is associated with pancreatic cancer progression and predicts poor prognosis.Cancer Biol Ther. 2019;20(9):1290-1299. doi: 10.1080/15384047.2019.1632143. Epub 2019 Jul 16.
164 Expression of signaling adaptor proteins predicts poor prognosis in pancreatic ductal adenocarcinoma.Diagn Pathol. 2017 May 30;12(1):42. doi: 10.1186/s13000-017-0633-4.
165 Cystatin F as a key family 2 cystatin subunit and prognostic biomarker for earlystage pancreatic ductal adenocarcinoma.Oncol Rep. 2019 Jul;42(1):79-90. doi: 10.3892/or.2019.7135. Epub 2019 Apr 24.
166 Clinical features of cystatin A expression in patients with pancreatic ductal adenocarcinoma.Cancer Sci. 2017 Nov;108(11):2122-2129. doi: 10.1111/cas.13396. Epub 2017 Oct 8.
167 Tumor-reducing effect of the clinically used drug clofazimine in a SCID mouse model of pancreatic ductal adenocarcinoma.Oncotarget. 2017 Jun 13;8(24):38276-38293. doi: 10.18632/oncotarget.11299.
168 Doublecortin and CaM kinase-like-1 as an independent prognostic factor in patients with resected pancreatic carcinoma.World J Gastroenterol. 2017 Aug 21;23(31):5764-5772. doi: 10.3748/wjg.v23.i31.5764.
169 High Phosphorylation Status of AKT/mTOR Signal in DESI2-Reduced Pancreatic Ductal Adenocarcinoma.Pathol Oncol Res. 2015 Apr;21(2):267-72. doi: 10.1007/s12253-014-9817-3. Epub 2014 Jul 31.
170 Dysbindin promotes progression of pancreatic ductal adenocarcinoma via direct activation of PI3K.J Mol Cell Biol. 2017 Dec 1;9(6):504-515. doi: 10.1093/jmcb/mjx043.
171 Dual oxidase 2 and pancreatic adenocarcinoma: IFN--mediated dual oxidase 2 overexpression results in H2O2-induced, ERK-associated up-regulation of HIF-1 and VEGF-A.Oncotarget. 2016 Oct 18;7(42):68412-68433. doi: 10.18632/oncotarget.12032.
172 EFNB2 acts as the target of miR-557 to facilitate cell proliferation, migration and invasion in pancreatic ductal adenocarcinoma by bioinformatics analysis and verification.Am J Transl Res. 2018 Nov 15;10(11):3514-3528. eCollection 2018.
173 EI24 Suppresses Tumorigenesis in Pancreatic Cancer via Regulating c-Myc.Gastroenterol Res Pract. 2018 Oct 2;2018:2626545. doi: 10.1155/2018/2626545. eCollection 2018.
174 Prognostic significance of EIF4G1 in patients with pancreatic ductal adenocarcinoma.Onco Targets Ther. 2019 Apr 15;12:2853-2859. doi: 10.2147/OTT.S202101. eCollection 2019.
175 Eukaryotic Translation Initiation Factor 3a (eIF3a) Promotes Cell Proliferation and Motility in Pancreatic Cancer.J Korean Med Sci. 2016 Oct;31(10):1586-94. doi: 10.3346/jkms.2016.31.10.1586.
176 Embigin is overexpressed in pancreatic ductal adenocarcinoma and regulates cell motility through epithelial to mesenchymal transition via the TGF- pathway.Mol Carcinog. 2016 May;55(5):633-45. doi: 10.1002/mc.22309. Epub 2015 Mar 14.
177 EYA4 functions as tumor suppressor gene and prognostic marker in pancreatic ductal adenocarcinoma through -catenin/ID2 pathway.Cancer Lett. 2016 Oct 1;380(2):403-412. doi: 10.1016/j.canlet.2016.06.021. Epub 2016 Jul 1.
178 FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma.J Exp Clin Cancer Res. 2018 Sep 10;37(1):224. doi: 10.1186/s13046-018-0888-y.
179 FEZF1-AS1/miR-107/ZNF312B axis facilitates progression and Warburg effect in pancreatic ductal adenocarcinoma.Cell Death Dis. 2018 Jan 18;9(2):34. doi: 10.1038/s41419-017-0052-1.
180 Membranous CD24 drives the epithelial phenotype of pancreatic cancer.Oncotarget. 2016 Aug 2;7(31):49156-49168. doi: 10.18632/oncotarget.9402.
181 Clinicopathological and prognostic significance of MUC13 and AGR2 expression in intraductal papillary mucinous neoplasms of the pancreas.Pancreatology. 2018 Jun;18(4):407-412. doi: 10.1016/j.pan.2018.04.003. Epub 2018 Apr 3.
182 GOLPH2, a gene downstream of ras signaling, promotes the progression of pancreatic ductal adenocarcinoma.Mol Med Rep. 2018 Mar;17(3):4187-4194. doi: 10.3892/mmr.2018.8430. Epub 2018 Jan 15.
183 High expression of microRNA-4295 contributes to cell proliferation and invasion of pancreatic ductal adenocarcinoma by the down-regulation of Glypican-5.Biochem Biophys Res Commun. 2018 Feb 26;497(1):73-79. doi: 10.1016/j.bbrc.2018.02.023. Epub 2018 Feb 3.
184 GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR.Cell Death Dis. 2016 Jul 14;7(7):e2294. doi: 10.1038/cddis.2016.169.
185 HMGN5 promotes proliferation and invasion via the activation of Wnt/-catenin signaling pathway in pancreatic ductal adenocarcinoma.Oncol Lett. 2018 Sep;16(3):4013-4019. doi: 10.3892/ol.2018.9090. Epub 2018 Jul 5.
186 Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma.J Cancer Res Clin Oncol. 2017 Jun;143(6):1061-1068. doi: 10.1007/s00432-017-2351-4. Epub 2017 Feb 17.
187 IGF2BP3 Modulates the Interaction of Invasion-Associated Transcripts with RISC.Cell Rep. 2016 May 31;15(9):1876-83. doi: 10.1016/j.celrep.2016.04.083. Epub 2016 May 19.
188 NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-B activation.Cancer Lett. 2017 Dec 28;411:44-56. doi: 10.1016/j.canlet.2017.09.018. Epub 2017 Sep 23.
189 The Insulin-Like Growth Factor 2 mRNA Binding Protein IMP2/IGF2BP2 is Overexpressed and Correlates with Poor Survival in Pancreatic Cancer.Int J Mol Sci. 2019 Jun 29;20(13):3204. doi: 10.3390/ijms20133204.
190 KLF10 loss in the pancreas provokes activation of SDF-1 and induces distant metastases of pancreatic ductal adenocarcinoma in the Kras(G12D) p53(flox/flox) model.Oncogene. 2017 Sep 28;36(39):5532-5543. doi: 10.1038/onc.2017.155. Epub 2017 Jun 5.
191 Latent Transforming Growth Factor Binding Protein 2 (LTBP2) as a Novel Biomarker for the Diagnosis and Prognosis of Pancreatic Carcinoma.Med Sci Monit. 2017 Jul 3;23:3232-3239. doi: 10.12659/msm.905284.
192 Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer.PLoS One. 2016 Mar 29;11(3):e0152300. doi: 10.1371/journal.pone.0152300. eCollection 2016.
193 Prognostic value of minichromosome maintenance mRNA expression in early-stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy.Cancer Manag Res. 2018 Sep 5;10:3255-3271. doi: 10.2147/CMAR.S171293. eCollection 2018.
194 PTEN-Dependent Stabilization of MTSS1 Inhibits Metastatic Phenotype in Pancreatic Ductal Adenocarcinoma.Neoplasia. 2018 Jan;20(1):12-24. doi: 10.1016/j.neo.2017.10.004. Epub 2017 Nov 23.
195 Clinical significance of MUC13 in pancreatic ductal adenocarcinoma.HPB (Oxford). 2018 Jun;20(6):563-572. doi: 10.1016/j.hpb.2017.12.003. Epub 2018 Jan 17.
196 Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine.Scand J Gastroenterol. 2017 May;52(5):595-600. doi: 10.1080/00365521.2017.1290134. Epub 2017 Feb 15.
197 High expression of diffuse panbronchiolitis critical region 1 gene promotes cell proliferation, migration and invasion in pancreatic ductal adenocarcinoma.Biochem Biophys Res Commun. 2018 Jan 8;495(2):1908-1914. doi: 10.1016/j.bbrc.2017.12.031. Epub 2017 Dec 11.
198 Clinicopathologic features and prognostic implications of MYBL2 protein expression in pancreatic ductal adenocarcinoma.Pathol Res Pract. 2017 Aug;213(8):964-968. doi: 10.1016/j.prp.2017.04.024. Epub 2017 May 4.
199 Myoferlin controls mitochondrial structure and activity in pancreatic ductal adenocarcinoma, and affects tumor aggressiveness.Oncogene. 2018 Aug;37(32):4398-4412. doi: 10.1038/s41388-018-0287-z. Epub 2018 May 3.
200 Nectin-1 expression in cancer-associated fibroblasts is a predictor of poor prognosis for pancreatic ductal adenocarcinoma.Surg Today. 2018 May;48(5):510-516. doi: 10.1007/s00595-017-1618-3. Epub 2017 Dec 18.
201 Association of cytosolic sialidase Neu2 with plasma membrane enhances Fas-mediated apoptosis by impairing PI3K-Akt/mTOR-mediated pathway in pancreatic cancer cells.Cell Death Dis. 2018 Feb 12;9(2):210. doi: 10.1038/s41419-017-0191-4.
202 Increased MTH1-specific 8-oxodGTPase activity is a hallmark of cancer in colon, lung and pancreatic tissue.DNA Repair (Amst). 2019 Nov;83:102644. doi: 10.1016/j.dnarep.2019.102644. Epub 2019 Jul 5.
203 Amphipathic helical peptides hamper protein-protein interactions of the intrinsically disordered chromatin nuclear protein 1 (NUPR1).Biochim Biophys Acta Gen Subj. 2018 Jun;1862(6):1283-1295. doi: 10.1016/j.bbagen.2018.03.009. Epub 2018 Mar 10.
204 OCIAD1 promoted pancreatic ductal adenocarcinoma migration by regulating ATM.Pancreatology. 2019 Jul;19(5):751-759. doi: 10.1016/j.pan.2019.01.009. Epub 2019 Jan 31.
205 Alpha-1-acid glycoprotein 1 is upregulated in pancreatic ductal adenocarcinoma and confers a poor prognosis.Transl Res. 2019 Oct;212:67-79. doi: 10.1016/j.trsl.2019.06.003. Epub 2019 Jun 29.
206 PAFAH1B2 is a HIF1a target gene and promotes metastasis in pancreatic cancer.Biochem Biophys Res Commun. 2018 Jun 27;501(3):654-660. doi: 10.1016/j.bbrc.2018.05.039. Epub 2018 May 16.
207 2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression.Cancer Lett. 2016 Apr 1;373(1):67-76. doi: 10.1016/j.canlet.2016.01.026. Epub 2016 Jan 21.
208 High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma.BMC Cancer. 2019 May 14;19(1):452. doi: 10.1186/s12885-019-5616-2.
209 Vasohibin-2 plays an essential role in metastasis of pancreatic ductal adenocarcinoma.Cancer Sci. 2019 Jul;110(7):2296-2308. doi: 10.1111/cas.14041. Epub 2019 Jun 18.
210 Dual Roles for CXCL4 Chemokines and CXCR3 in Angiogenesis and Invasion of Pancreatic Cancer.Cancer Res. 2016 Nov 15;76(22):6507-6519. doi: 10.1158/0008-5472.CAN-15-2864. Epub 2016 Sep 9.
211 PHLPP negatively regulates cell motility through inhibition of Akt activity and integrin expression in pancreatic cancer cells.Oncotarget. 2016 Feb 16;7(7):7801-15. doi: 10.18632/oncotarget.6848.
212 Expression of polymeric immunoglobulin receptor and stromal activity in pancreatic ductal adenocarcinoma.Pancreatology. 2017 Mar-Apr;17(2):295-302. doi: 10.1016/j.pan.2017.01.013. Epub 2017 Feb 1.
213 Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma.Proc Natl Acad Sci U S A. 2016 Mar 1;113(9):E1296-305. doi: 10.1073/pnas.1513801113. Epub 2016 Feb 16.
214 Homoharringtonine could induce quick protein synthesis of PSMD11 through activating MEK1/ERK1/2 signaling pathway in pancreatic cancer cells.J Cell Biochem. 2018 Aug;119(8):6644-6656. doi: 10.1002/jcb.26847. Epub 2018 Apr 17.
215 GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer.Gut. 2017 Sep;66(9):1665-1676. doi: 10.1136/gutjnl-2015-311256. Epub 2016 Jun 20.
216 Effects of Rab27A and Rab27B on Invasion, Proliferation, Apoptosis, and Chemoresistance in Human Pancreatic Cancer Cells.Pancreas. 2017 Oct;46(9):1173-1179. doi: 10.1097/MPA.0000000000000910.
217 Acceleration of pancreatic tumorigenesis under immunosuppressive microenvironment induced by Reg3g overexpression.Cell Death Dis. 2017 Sep 7;8(9):e3033. doi: 10.1038/cddis.2017.424.
218 Inhibition of renalase expression and signaling has antitumor activity in pancreatic cancer.Sci Rep. 2016 Mar 14;6:22996. doi: 10.1038/srep22996.
219 Ro60/SSA levels are increased and promote the progression of pancreatic ductal adenocarcinoma.Biochem Biophys Res Commun. 2018 Jan 22;495(4):2519-2524. doi: 10.1016/j.bbrc.2017.12.124. Epub 2017 Dec 22.
220 Protein salvador homolog 1 acts as a tumor suppressor and is modulated by hypermethylation in pancreatic ductal adenocarcinoma.Oncotarget. 2017 May 18;8(38):62953-62961. doi: 10.18632/oncotarget.17972. eCollection 2017 Sep 8.
221 Clinically approved PEGylated nanoparticles are covered by a protein corona that boosts the uptake by cancer cells.Nanoscale. 2017 Jul 27;9(29):10327-10334. doi: 10.1039/c7nr03042h.
222 Increased semaphorin 3c expression promotes tumor growth and metastasis in pancreatic ductal adenocarcinoma by activating the ERK1/2 signaling pathway.Cancer Lett. 2017 Jul 1;397:12-22. doi: 10.1016/j.canlet.2017.03.014. Epub 2017 Mar 14.
223 SERP1 is a novel marker of poor prognosis in pancreatic ductal adenocarcinoma patients via anti-apoptosis and regulating SRPRB/NF-B axis.Int J Oncol. 2017 Oct;51(4):1104-1114. doi: 10.3892/ijo.2017.4111. Epub 2017 Aug 31.
224 Promoter hypomethylation of SKI in autoimmune pancreatitis.Pathol Res Pract. 2018 Apr;214(4):492-497. doi: 10.1016/j.prp.2018.03.005. Epub 2018 Mar 6.
225 MiR-7-5p functions as a tumor suppressor by targeting SOX18 in pancreatic ductal adenocarcinoma.Biochem Biophys Res Commun. 2018 Mar 18;497(4):963-970. doi: 10.1016/j.bbrc.2018.02.005. Epub 2018 Mar 1.
226 SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.Oncogene. 2018 Feb 15;37(7):912-923. doi: 10.1038/onc.2017.393. Epub 2017 Oct 23.
227 Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer.Neoplasia. 2007 Jan;9(1):8-17. doi: 10.1593/neo.06646.
228 Overcoming chemoresistance in pancreatic cancer cells: role of the bitter taste receptor T2R10.J Cancer. 2018 Feb 1;9(4):711-725. doi: 10.7150/jca.21803. eCollection 2018.
229 APE1/Ref-1 knockdown in pancreatic ductal adenocarcinoma - characterizing gene expression changes and identifying novel pathways using single-cell RNA sequencing.Mol Oncol. 2017 Dec;11(12):1711-1732. doi: 10.1002/1878-0261.12138. Epub 2017 Oct 19.
230 MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma.J Exp Clin Cancer Res. 2018 Apr 3;37(1):76. doi: 10.1186/s13046-018-0739-x.
231 Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF- signaling pathway.J Exp Clin Cancer Res. 2019 Jul 15;38(1):310. doi: 10.1186/s13046-019-1313-x.
232 Thrombospondin-2 is a Highly Specific Diagnostic Marker and is Associated with Prognosis in Pancreatic Cancer.Ann Surg Oncol. 2019 Mar;26(3):807-814. doi: 10.1245/s10434-018-07109-6. Epub 2018 Dec 19.
233 ALPPL2 Is a Potential Diagnostic Biomarker for Pancreatic Cancer-Derived Extracellular Vesicles.Mol Ther Methods Clin Dev. 2019 Sep 12;15:204-210. doi: 10.1016/j.omtm.2019.08.016. eCollection 2019 Dec 13.
234 Circ-ASH2L promotes tumor progression by sponging miR-34a to regulate Notch1 in pancreatic ductal adenocarcinoma.J Exp Clin Cancer Res. 2019 Nov 12;38(1):466. doi: 10.1186/s13046-019-1436-0.
235 Five Novel Genes Related to the Pathogenesis and Progression of Pancreatic Neuroendocrine Tumors by Bioinformatics Analysis With RT-qPCR Verification.Front Neurosci. 2019 Sep 24;13:937. doi: 10.3389/fnins.2019.00937. eCollection 2019.
236 eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma.Nat Commun. 2019 Nov 13;10(1):5151. doi: 10.1038/s41467-019-13086-5.
237 Forkhead box B2 inhibits the malignant characteristics of the pancreatic cancer cell line Panc-1 in vitro.Genes Cells. 2019 Oct;24(10):674-681. doi: 10.1111/gtc.12717. Epub 2019 Oct 7.
238 Silencing of Neuropilins and GIPC1 in pancreatic ductal adenocarcinoma exerts multiple cellular and molecular antitumor effects.Sci Rep. 2019 Oct 29;9(1):15471. doi: 10.1038/s41598-019-51881-8.
239 Modeling Human Cancer-induced Cachexia.Cell Rep. 2019 Aug 6;28(6):1612-1622.e4. doi: 10.1016/j.celrep.2019.07.016.
240 RASAL2 Plays Inconsistent Roles in Different Cancers.Front Oncol. 2019 Nov 13;9:1235. doi: 10.3389/fonc.2019.01235. eCollection 2019.
241 IFN- down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer.BMC Cancer. 2019 Nov 6;19(1):1053. doi: 10.1186/s12885-019-6145-8.
242 lncRNA THAP9-AS1 Promotes Pancreatic Ductal Adenocarcinoma Growth and Leads to a Poor Clinical Outcome via Sponging miR-484 and Interacting with YAP.Clin Cancer Res. 2020 Apr 1;26(7):1736-1748. doi: 10.1158/1078-0432.CCR-19-0674. Epub 2019 Dec 12.
243 ADAM15 is involved in MICB shedding and mediates the effects of gemcitabine on MICB shedding in PANC-1 pancreatic cancer cells.Mol Med Rep. 2013 Mar;7(3):991-7. doi: 10.3892/mmr.2013.1272. Epub 2013 Jan 11.
244 SERPINB5 and AKAP12 - expression and promoter methylation of metastasis suppressor genes in pancreatic ductal adenocarcinoma.BMC Cancer. 2010 Oct 12;10:549. doi: 10.1186/1471-2407-10-549.
245 Shiga toxin glycosphingolipid receptor expression and toxin susceptibility of human pancreatic ductal adenocarcinomas of differing origin and differentiation.Biol Chem. 2012 Aug;393(8):785-99. doi: 10.1515/hsz-2012-0165.
246 Expression and prognostic significance of CD151, c-Met, and integrin alpha3/alpha6 in pancreatic ductal adenocarcinoma.Dig Dis Sci. 2011 Apr;56(4):1090-8. doi: 10.1007/s10620-010-1416-x. Epub 2010 Oct 7.
247 Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras.Clin Cancer Res. 2011 Oct 1;17(19):6140-50. doi: 10.1158/1078-0432.CCR-10-2288. Epub 2011 Aug 8.
248 Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression.Dev Cell. 2012 Jan 17;22(1):131-45. doi: 10.1016/j.devcel.2011.11.008. Epub 2011 Dec 22.
249 CLPTM1L promotes growth and enhances aneuploidy in pancreatic cancer cells.Cancer Res. 2014 May 15;74(10):2785-95. doi: 10.1158/0008-5472.CAN-13-3176. Epub 2014 Mar 19.
250 Pancreatic cancer-specific cell death induced in vivo by cytoplasmic-delivered polyinosine-polycytidylic acid.Cancer Res. 2014 Nov 1;74(21):6224-35. doi: 10.1158/0008-5472.CAN-14-0819. Epub 2014 Sep 9.
251 DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma.Tumour Biol. 2013 Oct;34(5):2857-61. doi: 10.1007/s13277-013-0846-4. Epub 2013 May 17.
252 Quantitative proteomic profiling identifies DPYSL3 as pancreatic ductal adenocarcinoma-associated molecule that regulates cell adhesion and migration by stabilization of focal adhesion complex.PLoS One. 2013 Dec 5;8(12):e79654. doi: 10.1371/journal.pone.0079654. eCollection 2013.
253 Epithelial splicing regulatory protein 1 is a favorable prognostic factor in pancreatic cancer that attenuates pancreatic metastases.Oncogene. 2014 Sep 4;33(36):4485-95. doi: 10.1038/onc.2013.392. Epub 2013 Sep 30.
254 FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer.Cancer Res. 2013 Sep 1;73(17):5416-25. doi: 10.1158/0008-5472.CAN-13-0362. Epub 2013 Jun 25.
255 The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma.Tumour Biol. 2015 Dec;36(12):9961-8. doi: 10.1007/s13277-015-3752-0. Epub 2015 Jul 16.
256 Overexpression of GOLPH3 is associated with poor prognosis and clinical progression in pancreatic ductal adenocarcinoma.BMC Cancer. 2014 Aug 7;14:571. doi: 10.1186/1471-2407-14-571.
257 Expression of HOXC8 is inversely related to the progression and metastasis of pancreatic ductal adenocarcinoma.Br J Cancer. 2011 Jul 12;105(2):288-95. doi: 10.1038/bjc.2011.217. Epub 2011 Jun 28.
258 NF45 overexpression is associated with poor prognosis and enhanced cell proliferation of pancreatic ductal adenocarcinoma.Mol Cell Biochem. 2015 Dec;410(1-2):25-35. doi: 10.1007/s11010-015-2535-7. Epub 2015 Aug 15.
259 Integrated microRNA-mRNA analysis of pancreatic ductal adenocarcinoma.Genet Mol Res. 2015 Aug 28;14(3):10288-97. doi: 10.4238/2015.August.28.14.
260 Oncogenicity of LHX2 in pancreatic ductal adenocarcinoma.Mol Biol Rep. 2014 Dec;41(12):8163-7. doi: 10.1007/s11033-014-3716-2. Epub 2014 Oct 17.
261 Transforming Growth Factor TGF Increases Levels of Microtubule-Associated Protein MAP1S and Autophagy Flux in Pancreatic Ductal Adenocarcinomas.PLoS One. 2015 Nov 16;10(11):e0143150. doi: 10.1371/journal.pone.0143150. eCollection 2015.
262 Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis.J Clin Invest. 2014 Mar;124(3):1069-82. doi: 10.1172/JCI67280.
263 Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway.Cancer Lett. 2009 May 8;277(1):72-81. doi: 10.1016/j.canlet.2008.11.028. Epub 2008 Dec 31.
264 Alternative splicing of NUMB, APP and VEGFA as the features of pancreatic ductal carcinoma.Int J Clin Exp Pathol. 2015 Jun 1;8(6):6181-91. eCollection 2015.
265 High expression of ErbB3 binding protein 1 (EBP1) predicts poor prognosis of pancreatic ductal adenocarcinoma (PDAC).Tumour Biol. 2015 Dec;36(12):9189-99. doi: 10.1007/s13277-015-3625-6. Epub 2015 Jun 19.
266 Clinicopathological and prognostic significance of myofibrillogenesis regulator-1 protein expression in pancreatic ductal adenocarcinoma.Tumour Biol. 2013 Oct;34(5):2983-7. doi: 10.1007/s13277-013-0862-4. Epub 2013 May 22.
267 Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.PLoS One. 2015 Jun 8;10(6):e0129012. doi: 10.1371/journal.pone.0129012. eCollection 2015.
268 Quiescin sulfhydryl oxidase 1 promotes invasion of pancreatic tumor cells mediated by matrix metalloproteinases.Mol Cancer Res. 2011 Dec;9(12):1621-31. doi: 10.1158/1541-7786.MCR-11-0018. Epub 2011 Oct 11.
269 Response to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation.Mol Cancer Ther. 2014 Jan;13(1):122-33. doi: 10.1158/1535-7163.MCT-12-1232. Epub 2013 Nov 12.
270 Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.World J Gastroenterol. 2015 Jun 7;21(21):6621-30. doi: 10.3748/wjg.v21.i21.6621.
271 Snail recruits Ring1B to mediate transcriptional repression and cell migration in pancreatic cancer cells.Cancer Res. 2014 Aug 15;74(16):4353-63. doi: 10.1158/0008-5472.CAN-14-0181. Epub 2014 Jun 5.
272 SRPX2 promotes cell migration and invasion via FAK dependent pathway in pancreatic cancer.Int J Clin Exp Pathol. 2015 May 1;8(5):4791-8. eCollection 2015.
273 SCL/TAL1 interrupting locus derepresses GLI1 from the negative control of suppressor-of-fused in pancreatic cancer cell.Cancer Res. 2008 Oct 1;68(19):7723-9. doi: 10.1158/0008-5472.CAN-07-6661.
274 Low expression of TBX4 predicts poor prognosis in patients with stage II pancreatic ductal adenocarcinoma.Int J Mol Sci. 2011;12(8):4953-63. doi: 10.3390/ijms12084953. Epub 2011 Aug 3.
275 TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.PLoS One. 2015 Dec 28;10(12):e0144969. doi: 10.1371/journal.pone.0144969. eCollection 2015.
276 TRIM29 as a novel biomarker in pancreatic adenocarcinoma.Dis Markers. 2014;2014:317817. doi: 10.1155/2014/317817. Epub 2014 Apr 22.
277 Involvement of the tubulin tyrosine ligase-like family member 4 polyglutamylase in PELP1 polyglutamylation and chromatin remodeling in pancreatic cancer cells.Cancer Res. 2010 May 15;70(10):4024-33. doi: 10.1158/0008-5472.CAN-09-4444. Epub 2010 May 4.
278 Stromal responses to carcinomas of the pancreas: juxtatumoral gene expression conforms to the infiltrating pattern and not the biologic subtype.Cancer Biol Ther. 2005 Mar;4(3):302-7. doi: 10.4161/cbt.4.3.1501. Epub 2005 Mar 23.
279 Tumor-associated macrophages promote progression and the Warburg effect via CCL18/NF-kB/VCAM-1 pathway in pancreatic ductal adenocarcinoma.Cell Death Dis. 2018 May 1;9(5):453. doi: 10.1038/s41419-018-0486-0.
280 Utilization of CDX2 expression in diagnosing pancreatic ductal adenocarcinoma and predicting prognosis.PLoS One. 2014 Jan 29;9(1):e86853. doi: 10.1371/journal.pone.0086853. eCollection 2014.
281 KIAA1199 is induced by inflammation and enhances malignant phenotype in pancreatic cancer.Oncotarget. 2017 Mar 7;8(10):17156-17163. doi: 10.18632/oncotarget.15052.
282 CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.Oncotarget. 2016 Mar 22;7(12):14831-40. doi: 10.18632/oncotarget.7447.
283 Biphasic and Stage-Associated Expression of CPEB4 in Hepatocellular Carcinoma.PLoS One. 2016 May 9;11(5):e0155025. doi: 10.1371/journal.pone.0155025. eCollection 2016.
284 CRABP-II enhances pancreatic cancer cell migration and invasion by stabilizing interleukin 8 expression.Oncotarget. 2016 Dec 26;8(32):52432-52444. doi: 10.18632/oncotarget.14194. eCollection 2017 Aug 8.
285 MiR-361-3p regulates ERK1/2-induced EMT via DUSP2 mRNA degradation in pancreatic ductal adenocarcinoma.Cell Death Dis. 2018 Jul 24;9(8):807. doi: 10.1038/s41419-018-0839-8.
286 Prognostic value of Kindlin-2 expression in patients with solid tumors: a meta-analysis.Cancer Cell Int. 2018 Oct 22;18:166. doi: 10.1186/s12935-018-0651-7. eCollection 2018.
287 CD63-GPC1-Positive Exosomes Coupled with CA19-9 Offer Good Diagnostic Potential for Resectable Pancreatic Ductal Adenocarcinoma.Transl Oncol. 2019 Nov;12(11):1395-1403. doi: 10.1016/j.tranon.2019.07.009. Epub 2019 Aug 7.
288 HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival.Cancer Lett. 2019 Feb 1;442:333-340. doi: 10.1016/j.canlet.2018.11.007. Epub 2018 Nov 14.
289 Acetylated HOXB9 at lysine 27 is of differential diagnostic value in patients with pancreatic ductal adenocarcinoma.Front Med. 2020 Feb;14(1):91-100. doi: 10.1007/s11684-019-0696-6. Epub 2019 Aug 2.
290 Insulin-like growth factor 2 mRNA binding protein 2 promotes aerobic glycolysis and cell proliferation in pancreatic ductal adenocarcinoma via stabilizing GLUT1 mRNA.Acta Biochim Biophys Sin (Shanghai). 2019 Jul 10;51(7):743-752. doi: 10.1093/abbs/gmz048.
291 Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma.Amino Acids. 2017 Aug;49(8):1325-1335. doi: 10.1007/s00726-017-2430-5. Epub 2017 May 23.
292 IQGAP1 Maintains Pancreatic Ductal Adenocarcinoma Clonogenic Growth and Metastasis.Pancreas. 2019 Jan;48(1):94-98. doi: 10.1097/MPA.0000000000001198.
293 Krppel-like factor 9 suppressed tumorigenicity of the pancreatic ductal adenocarcinoma by negatively regulating frizzled-5.Biochem Biophys Res Commun. 2018 May 23;499(4):815-821. doi: 10.1016/j.bbrc.2018.03.229. Epub 2018 Apr 4.
294 Profiling of different pancreatic cancer cells used as models for metastatic behaviour shows large variation in their N-glycosylation.Sci Rep. 2017 Nov 30;7(1):16623. doi: 10.1038/s41598-017-16811-6.
295 LRG-1 promotes pancreatic cancer growth and metastasis via modulation of the EGFR/p38 signaling.J Exp Clin Cancer Res. 2019 Feb 13;38(1):75. doi: 10.1186/s13046-019-1088-0.
296 Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarcinoma.Cell Death Differ. 2019 Jan;26(2):382-393. doi: 10.1038/s41418-018-0207-3. Epub 2018 Oct 3.
297 MTA2-mediated inhibition of PTEN leads to pancreatic ductal adenocarcinoma carcinogenicity.Cell Death Dis. 2019 Feb 27;10(3):206. doi: 10.1038/s41419-019-1424-5.
298 Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway.Oncogene. 2018 Nov;37(46):6041-6053. doi: 10.1038/s41388-018-0403-0. Epub 2018 Jul 11.
299 Nardilysin inhibits pancreatitis and suppresses pancreatic ductal adenocarcinoma initiation in mice.Gut. 2019 May;68(5):882-892. doi: 10.1136/gutjnl-2017-315425. Epub 2018 May 24.
300 High-resolution genomic profiles of human lung cancer.Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9625-30. doi: 10.1073/pnas.0504126102. Epub 2005 Jun 27.
301 Evidence of (68)Ga-DOTA-NT-20.3 Uptake in Pancreatic Adenocarcinoma AsPC-1 Cell Line - in vitro Study.Curr Pharm Biotechnol. 2018;19(9):754-759. doi: 10.2174/1389201019666180829152314.
302 Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma.Sci Rep. 2018 May 25;8(1):8105. doi: 10.1038/s41598-018-26526-x.
303 Prevalence and Progression of Pancreatic Cystic Precursor Lesions Differ Between Groups at High Risk of Developing Pancreatic Cancer.Pancreas. 2017 Jan;46(1):28-34. doi: 10.1097/MPA.0000000000000725.
304 Multifaceted peptide assisted one-pot synthesis of gold nanoparticles for plectin-1 targeted gemcitabine delivery in pancreatic cancer.Nanoscale. 2017 Oct 19;9(40):15622-15634. doi: 10.1039/c7nr03172f.
305 High expression of protein phosphatase 4 is associated with the aggressive malignant behavior of colorectal carcinoma.Mol Cancer. 2015 Apr 28;14:95. doi: 10.1186/s12943-015-0356-7.
306 Induced PTF1a expression in pancreatic ductal adenocarcinoma cells activates acinar gene networks, reduces tumorigenic properties, and sensitizes cells to gemcitabine treatment.Mol Oncol. 2018 Jun;12(7):1104-1124. doi: 10.1002/1878-0261.12314. Epub 2018 May 21.
307 Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas.Br J Cancer. 1998;77(1):147-52. doi: 10.1038/bjc.1998.23.
308 Putative tumor suppressor gene SEL1L was downregulated by aberrantly upregulated hsa-mir-155 in human pancreatic ductal adenocarcinoma.Mol Carcinog. 2014 Sep;53(9):711-21. doi: 10.1002/mc.22023. Epub 2013 May 9.
309 Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer.Mol Cancer. 2019 May 20;18(1):96. doi: 10.1186/s12943-019-1023-1.
310 Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?.Autophagy. 2019 Feb;15(2):368-371. doi: 10.1080/15548627.2018.1509609. Epub 2018 Sep 13.
311 Rho guanine nucleotide exchange factor ARHGEF10 is a putative tumor suppressor in pancreatic ductal adenocarcinoma.Oncogene. 2020 Jan;39(2):308-321. doi: 10.1038/s41388-019-0985-1. Epub 2019 Sep 2.
312 Correction: Prorenin receptor acts as a potential molecular target for pancreatic ductal adenocarcinoma diagnosis.Oncotarget. 2019 Jan 11;10(4):558. doi: 10.18632/oncotarget.26597. eCollection 2019 Jan 11.
313 Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma.J Exp Med. 2019 Mar 4;216(3):656-673. doi: 10.1084/jem.20180749. Epub 2019 Feb 7.
314 Gene regulation by antitumor miR-130b-5p in pancreatic ductal adenocarcinoma: the clinical significance of oncogenic EPS8.J Hum Genet. 2019 Jun;64(6):521-534. doi: 10.1038/s10038-019-0584-6. Epub 2019 Mar 11.
315 FASTKD2 promotes cancer cell progression through upregulating Myc expression in pancreatic ductal adenocarcinoma.J Cell Biochem. 2020 Mar;121(3):2458-2466. doi: 10.1002/jcb.29468. Epub 2019 Nov 6.
316 Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma.Oncogene. 2019 Jun;38(26):5308-5320. doi: 10.1038/s41388-019-0794-6. Epub 2019 Mar 27.
317 Insulinoma-associated protein 1 expression in pancreatic neuroendocrine tumours in endoscopic ultrasound-guided fine-needle aspiration cytology: An analysis of 14 patients.Cytopathology. 2019 Mar;30(2):194-200. doi: 10.1111/cyt.12640. Epub 2018 Dec 17.
318 KAT2A succinyltransferase activity-mediated 14-3-3 upregulation promotes -catenin stabilization-dependent glycolysis and proliferation of pancreatic carcinoma cells.Cancer Lett. 2020 Jan 28;469:1-10. doi: 10.1016/j.canlet.2019.09.015. Epub 2019 Oct 11.
319 HBXIP protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.Pathol Res Pract. 2019 Feb;215(2):343-346. doi: 10.1016/j.prp.2018.12.016. Epub 2018 Dec 12.
320 LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen-Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation.Clin Cancer Res. 2019 Jul 1;25(13):4091-4103. doi: 10.1158/1078-0432.CCR-18-3533. Epub 2019 Jan 24.
321 TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status.Autophagy. 2020 Mar;16(3):486-500. doi: 10.1080/15548627.2019.1628540. Epub 2019 Jun 17.
322 Clinicopathological and prognostic significance of MKK4 and MKK7 in resectable pancreatic ductal adenocarcinoma.Hum Pathol. 2019 Apr;86:143-154. doi: 10.1016/j.humpath.2018.11.026. Epub 2018 Dec 9.
323 MDH1 and MPP7 Regulate Autophagy in Pancreatic Ductal Adenocarcinoma.Cancer Res. 2019 Apr 15;79(8):1884-1898. doi: 10.1158/0008-5472.CAN-18-2553. Epub 2019 Feb 14.
324 Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites.EBioMedicine. 2019 Feb;40:394-405. doi: 10.1016/j.ebiom.2019.01.037. Epub 2019 Jan 30.
325 Adipophilin expression is an indicator of poor prognosis in patients with pancreatic ductal adenocarcinoma: An immunohistochemical analysis.Pancreatology. 2019 Apr;19(3):443-448. doi: 10.1016/j.pan.2019.03.001. Epub 2019 Mar 11.
326 POLE Score: a comprehensive profiling of programmed death 1 ligand 1 expression in pancreatic ductal adenocarcinoma.Oncotarget. 2019 Feb 22;10(16):1572-1588. doi: 10.18632/oncotarget.26705. eCollection 2019 Feb 22.
327 Gene Regulation by Antitumor miR-204-5p in Pancreatic Ductal Adenocarcinoma: The Clinical Significance of Direct RACGAP1 Regulation.Cancers (Basel). 2019 Mar 7;11(3):327. doi: 10.3390/cancers11030327.
328 Downregulation of thymopoietin by miR-139-5p suppresses cell proliferation and induces cell cycle arrest/apoptosis in pancreatic ductal adenocarcinoma.Oncol Lett. 2019 Oct;18(4):3443-3452. doi: 10.3892/ol.2019.10679. Epub 2019 Jul 29.